Keros Therapeutics (KROS) Treasury Shares (2019 - 2025)

Keros Therapeutics (KROS) posted Treasury Shares of $21.1 million for Q4 2025, up 2827.36% on a QoQ basis from $721700.0 in Q3 2025.

Keros Therapeutics (KROS) Treasury Shares (2019 - 2025) Analysis & Trends

Keros Therapeutics' Treasury Shares history runs 1 years deep, the most recent figure standing at $384.6 million for Q4 2025.

Quarterly Treasury Shares changed N/A year-over-year to $21.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $21.1 million (changed N/A YoY) and the FY2025 annual result came in at $21.1 million, changed N/A from the prior year.
Treasury Shares was $384.6 million for Q4 2025 at Keros Therapeutics.
Across five years, Treasury Shares topped out at $21.1 million in Q4 2025 and bottomed at $721700.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-21,709.08
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	265,401.92
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	19.41 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	5.14 Mn
10	Keros Therapeutics	377.42 Mn	90.02 Mn	-	21.13 Mn

Download Data